Preferred Label : Nivolumab and Recombinant Human Hyaluronidase;
NCIt synonyms : Nivolumab/Recombinant Human Hyaluronidase; Nivolumab and rHuPH20; Nivolumab and Hyaluronidase-nvhy; Hyaluronidase-nvhy and Nivolumab; Nivolumab/rHuPH20; Hyaluronidase/Nivolumab;
NCIt definition : A co-formulation composed of nivolumab, a fully human immunoglobulin G4 (IgG4) monoclonal
antibody directed against the negative immunoregulatory human cell surface receptor
programmed cell death protein 1 (PD-1; PDCD1; CD279), and a recombinant form of human
hyaluronidase, with potential immune checkpoint inhibitory and antineoplastic activities.
Upon subcutaneous administration of nivolumab and recombinant human hyaluronidase,
nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily
(IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1),
which is overexpressed on certain cancer cells, and programmed cell death ligand 2
(PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results
in the activation of T-cells and cell-mediated immune responses against tumor cells.
Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor
evasion from host immunity. Hyaluronidase hydrolyzes and degrades the glycosaminoglycan
hyaluronic acid (HA), thereby decreasing interstitial viscosity and enhancing penetration
of nivolumab through the interstitial space. This facilitates the delivery of nivolumab.;
Drug name : Opdivo Qvantig;
Origin ID : C212985;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
